Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Nov 14;13(42):5618-28.
doi: 10.3748/wjg.v13.i42.5618.

Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions

Quan Zhou  1 , Xiao-Feng Yan, Zhong-Miao Zhang, Wen-Sheng Pan, Su Zeng
Affiliations
Review

Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions

Quan Zhou et al. World J Gastroenterol. .

Abstract

Aim: To review and summarize drug metabolism and its related interactions in prescribing drugs within the similar therapeutic or structural class for gastrointestinal disease treatment so as to promote rational use of medicines in clinical practice.

Methods: Relevant literature was identified by performing MEDLINE/Pubmed searches covering the period from 1988 to 2006.

Results: Seven classes of drugs were chosen, including gastric proton pump inhibitors, histamine H(2)-receptor antagonists, benzamide-type gastroprokinetic agents, selective 5-HT(3) receptor antagonists, fluoroquinolones, macrolide antibiotics and azole antifungals. They showed significant differences in metabolic profile (i.e., the fraction of drug metabolized by cytochrome P450 (CYP), CYP reaction phenotype, impact of CYP genotype on interindividual pharmacokinetics variability and CYP-mediated drug-drug interaction potential). Many events of severe adverse drug reactions and treatment failures were closely related to the ignorance of the above issues.

Conclusion: Clinicians should acquaint themselves with what kind of drug has less interpatient variability in clearance and whether to perform CYP genotyping prior to initiation of therapy. The relevant CYP knowledge helps clinicians to enhance the management of patients with gastrointestinal disease who may require treatment with polytherapeutic regimens.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of five PPIs.
Figure 2
Figure 2
Metabolic differences between four PPIs (OME: omeprazole; LAN: lansoprazole; RAB: rabeprazole; PAN: Pantoprazole). Arrow thickness represents relative contribution to metabolism.
Figure 3
Figure 3
Stereoselective metabolism of omprazole in human.
Figure 4
Figure 4
Chemical structures of six H2-receptor antagonists.
Figure 5
Figure 5
Chemical structures of seven benzamide-type gastroprokinetic agents.
Figure 6
Figure 6
Chemical structures of eight setrons.
Figure 7
Figure 7
Chemical structures of nine fluoroquinolones.
Figure 8
Figure 8
Chemical structures of four azole antifungals.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ansede JH, Thakker DR. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci. 2004;93:239–255. - PubMed
    1. Lewis DF, Modi S, Dickins M. Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. Drug Metabol Drug Interact. 2001;18:221–242. - PubMed
    1. Lewis DF, Modi S, Dickins M. Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002;34:69–82. - PubMed
    1. FDA Guidance for industry drug metabolism/drug interaction studies in the drug development process: studies in vitro. April 1997. Available from: http: //www.fda.gov/cder/guidance/clin3.pdf.
    1. FDA Guidance for Industry In Vivo Drug Metabolism/Drug Interaction Studies -Study Design, Data Analysis, and Recommendations for Dosing and Labeling. November 1999. Available from: http: //www.fda.gov/cber/gdlns/metabol.htm.

Publication types

MeSH terms